Celia Maria Silva Pedrosa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Celia Maria Silva Pedrosa has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Eliana Maria Mauricio da Rocha
1 shared publication- Lindon Johoson Diniz Silveira
Specialist in Health Sciences from the University of Health Sciences of Alagoas-UNCISAL, University Center Cesmac
1 shared publication Ricardo Arraes de Alencar Ximenes
1 shared publication- Sandra Aparecida Ribeiro
PhD in Medicine (Pulmonology) Federal University of São Paulo, Associate Professor, Department of Preventive Medicine, Federal University of São Paulo
1 shared publication - Thiago José Matos Rocha
Universidade Estadual de Ciências da Saúde de Alagoas
1 shared publication Wendell Alexandre Pinheiro de Almeida
1 shared publication
Latest Publications
- Open Access
- 1 March 2017
- Published by IntechOpen
Clinical Manifestations of Visceral Leishmaniasis (American Visceral Leishmaniasis)
Clinical Manifestations of Visceral Leishmaniasis (American Visceral Leishmaniasis) | InTechOpen, Published on: 2017-03-01. Authors: Celia M.S. Pedrosa
- 1 March 2017
- Published by IntechOpen
Open AccessClinical Manifestations of Visceral Leishmaniasis (American Visceral Leishmaniasis)
Clinical Manifestations of Visceral Leishmaniasis (American Visceral Leishmaniasis) | InTechOpen, Published on: 2017-03-01. Authors: Celia M.S. Pedrosa
- Open Access
- 1 February 2015
- Published by FapUNIFESP (SciELO) in Revista do Instituto de Medicina Tropical de São Paulo
- Vol. 57 (1) , 33-38
HISTORICAL SERIES OF PATIENTS WITH VISCERAL LEISHMANIASIS TREATED WITH MEGLUMINE ANTIMONIATE IN A HOSPITAL FOR TROPICAL DISEASES, MACEIÓ-AL, BRAZIL
Introduction: Visceral leishmaniasis is an endemic protozoan found in Brazil. It is characterized by fever, pallor, hepatosplenomegaly, lymphadenopathy, and progressive weakness in the patient. It may lead to death if untreated. The drug of choice for treatment is meglumine antimoniate (Glucantime®). The aim of this study was to evaluate patients with visceral leishmaniasis according to criteria used for diagnosis, possible reactions to Glucantime® and blood pressure measured before and after treatment. Methods: 89 patients admitted to the Teaching Hospital Dr. Hélvio Auto (HEHA) in Maceió-AL, in the period from May 2006 to December 2009 were evaluated. Data were collected on age, sex, origin, method of diagnosis, adverse effects of drugs, duration of hospitalization, duration of treatment and dosage up to the onset of adverse effects. Results: There was a predominance of child male patients, aged between one and five years old, from the interior of the State of Alagoas. Parasitological diagnosis was made by bone marrow aspirate; three (3.37%) patients died, 12 (13.48%) had adverse reactions and treatment was changed to amphotericin B, and 74 (83.14%) were cured. Changes that led to replacing Glucantime® were persistent fever, jaundice, rash, bleeding and cyanosis. Conclusion: During the study, 89 patients hospitalized for VL were analyzed: 74 were healed, 12 were replaced by amphotericin B treatment and three died. Most of them were under five years old, male and came from the interior. The dosage and duration of treatment with Glucantime® were consistent with that advocated by the Ministry of Health. Persistence of fever, jaundice, rash, cyanosis and bleeding were the reactions that led the physician to modify treatment. No change was observed in blood pressure before and after treatment. This study demonstrated the work of a hospital, a reference in the treatment of leishmaniasis, which has many patients demanding its services in this area. It demonstrates that this disease is still important today, and needs to be addressed properly to prevent injury and death due to the disease.
- 1 February 2015
- Published by FapUNIFESP (SciELO) in Revista do Instituto de Medicina Tropical de São Paulo
- Vol. 57 (1) , 33-38
Open AccessHISTORICAL SERIES OF PATIENTS WITH VISCERAL LEISHMANIASIS TREATED WITH MEGLUMINE ANTIMONIATE IN A HOSPITAL FOR TROPICAL DISEASES, MACEIÓ-AL, BRAZIL
Introduction: Visceral leishmaniasis is an endemic protozoan found in Brazil. It is characterized by fever, pallor, hepatosplenomegaly, lymphadenopathy, and progressive weakness in the patient. It may lead to death if untreated. The drug of choice for treatment is meglumine antimoniate (Glucantime®). The aim of this study was to evaluate patients with visceral leishmaniasis according to criteria used for diagnosis, possible reactions to Glucantime® and blood pressure measured before and after treatment. Methods: 89 patients admitted to the Teaching Hospital Dr. Hélvio Auto (HEHA) in Maceió-AL, in the period from May 2006 to December 2009 were evaluated. Data were collected on age, sex, origin, method of diagnosis, adverse effects of drugs, duration of hospitalization, duration of treatment and dosage up to the onset of adverse effects. Results: There was a predominance of child male patients, aged between one and five years old, from the interior of the State of Alagoas. Parasitological diagnosis was made by bone marrow aspirate; three (3.37%) patients died, 12 (13.48%) had adverse reactions and treatment was changed to amphotericin B, and 74 (83.14%) were cured. Changes that led to replacing Glucantime® were persistent fever, jaundice, rash, bleeding and cyanosis. Conclusion: During the study, 89 patients hospitalized for VL were analyzed: 74 were healed, 12 were replaced by amphotericin B treatment and three died. Most of them were under five years old, male and came from the interior. The dosage and duration of treatment with Glucantime® were consistent with that advocated by the Ministry of Health. Persistence of fever, jaundice, rash, cyanosis and bleeding were the reactions that led the physician to modify treatment. No change was observed in blood pressure before and after treatment. This study demonstrated the work of a hospital, a reference in the treatment of leishmaniasis, which has many patients demanding its services in this area. It demonstrates that this disease is still important today, and needs to be addressed properly to prevent injury and death due to the disease.
- Open Access
- 30 June 2013
- Published by Elsevier in The Brazilian Journal of Infectious Diseases
- Vol. 17 (3) , 319-323
Validity of the polymerase chain reaction in the diagnosis of clinically suspected cases of American visceral leishmaniasis
- 30 June 2013
- Published by Elsevier in The Brazilian Journal of Infectious Diseases
- Vol. 17 (3) , 319-323
Open AccessValidity of the polymerase chain reaction in the diagnosis of clinically suspected cases of American visceral leishmaniasis